Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

Summary

This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to measure patient satisfaction with and preference of intranasal corticosteroids (INCS) for the treatment of allergic rhinitis (AR), is utilized in this study.

Timeline

Start

2011-07

Primary completion

2011-11

Completion

2011-11

Outcome

Met primary endpoint

paper A total of 68.1% of subjects preferred CIC-HFA (p < 0.0001 versus MFNS), with a mean TPS of 68.3 versus 31.7 for the MFNS group. PMID 24169063 ↗

paper The regimen attributes composite satisfaction score significantly (p < 0.0001 for each treatment period) favored CIC-HFA versus MFNS PMID 24169063 ↗

Publications

• Berger WE, Prenner B, Turner R, Meltzer EO. A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2013 Nov-Dec;34(6):542-50. doi: 10.2500/aap.2013.34.3705.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ciclesonide	Other / unclassified	74 ug	Intranasal
Comparator	Mometasone	Other / unclassified	200 ug	Intranasal

Indications